Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Stapokibart Efficacy in CRSwNP
NCT06801353Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Beijing Tongren Hospital. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06801353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801353.